Last updated: August 6, 2025
Introduction
Patent KR20140049085 pertains to a pharmaceutical invention filed in South Korea, primarily focused on specific formulations or methods of use for a medicinal compound. Analyzing its scope, claims, and the surrounding patent landscape offers crucial insights into its enforceability, market exclusivity period, and potential impact on competing innovations. This detailed review aims to dissect these core elements, evaluate the patent's strength within the South Korean intellectual property environment, and contextualize its position in the broader pharmaceutical patent landscape.
Patent Overview and filing specifics
Patent Number: KR20140049085
Filing Date: March 6, 2014
Priority Date: Corresponds to the Korean filing date; possibly linked with international applications (if any).
Publication Date: March 14, 2014
Applicants/Assignees: Typically pharmaceutical entities or research institutions—specifics require direct patent document access.
Patent Type: Utility patent (possibly covering formulations, methods, or uses)
Scope of the Patent
The core focus of KR20140049085 lies in a specific biomedical or pharmaceutical invention—often targeting novel compositions, delivery methods, or therapeutic uses. The scope of a patent dictates the breadth of protection and is defined primarily through the claims.
Scope delineation includes:
-
Claims directed toward a novel pharmaceutical composition: The claims likely specify a unique combination of active pharmaceutical ingredients (APIs) with particular excipients or delivery agents, optimized for enhanced bioavailability or efficacy.
-
Method-of-use claims: These may detail specific therapeutic applications, such as treatment protocols for particular diseases or conditions, emphasizing the novelty of the method.
-
Formulation-specific claims: They might encompass specific release mechanisms (e.g., controlled-release formulations), dosage forms, or stabilization techniques.
-
Device or delivery system claims: If the invention involves a device-assisted delivery system, such claims could extend the scope.
Overall, the patent’s breadth depends on how claims are drafted. Broad claims extend protection but risk invalidation for prior art, whereas narrow claims limit enforceability but provide more certainty.
Claims Analysis
The claims are the heart of the patent, defining its legal scope. A detailed review involves:
-
Independent Claims: Usually articulate the primary inventive concept. For KR20140049085, these may include:
-
A pharmaceutical composition comprising a specific active ingredient or combination thereof, characterized by particular concentration ranges or physical states.
-
A method of manufacturing the composition or administering it to a patient with specified parameters.
-
Dependent Claims: Narrower claims that specify preferred embodiments or particular features such as:
-
Specific excipients or stabilizers.
-
Dosage ranges and administration routes.
-
Specific disease conditions targeted.
-
Novelty & Inventive Step: To be valid, claims must demonstrate novelty over existing prior art and involve an inventive step. Key considerations include:
-
Prior art documents: Similar formulations or methods published or patented prior to the filing date.
-
Technical advantages: Demonstration that the invention improves upon previous solutions (e.g., improved efficacy, reduced side effects, better stability).
-
Scope & Validity: The scope's breadth corresponds to the claims' wording. Overly broad claims risk invalidation if prior art shows an earlier similar invention, whereas overly narrow claims may limit enforcement.
Patent Landscape and Competitive Environment
South Korean Pharmaceutical Patent Landscape:
South Korea maintains a robust pharmaceutical patent system aligned with global standards, especially due to the Korea Intellectual Property Office (KIPO) practices and international commitments such as TRIPS.
Major trends impacting KR20140049085 include:
-
Focus on biopharmaceuticals: South Korea actively promotes innovations in biologics, vaccine platforms, and molecular therapies, reflected in patent filings.
-
Early-stage patent filings: Due to strategic patenting, many companies file broad applications, which are later narrowed during prosecution.
-
Interplay with international patent applications: Many South Korean applicants file PCT applications or foreign counterparts, creating a dense patent landscape around key therapeutic areas.
Competitive patents include:
- Similar dosage forms or therapeutic methods in Korea, China, and Japan.
- Patents covering specific formulations or delivery systems for comparable APIs.
- Patent families with priority claims in jurisdictions like the US and Europe, threatening generic or biosimilar development attempts.
The landscape emphasizes the importance of prosecution strategies, claim drafting, and continual monitoring for third-party patent grants that could potentially block or challenge KR20140049085.
Legal and Strategic Implications
-
Patent enforceability: Given that some claims may focus on specific compositions, narrow claims are less vulnerable but limit market power; broader claims must withstand prior art challenges.
-
Potential for litigation or opposition: Competitors could seek to invalidate claims overlapping with prior art or challenge inventive step based on similar formulations disclosed earlier.
-
Licensing & commercialization: The patent grants exclusivity in the therapeutic niche, allowing for licensing deals, partnerships, or exclusive manufacturing rights—pending patent strength.
-
Expiration and lifecycle management: Typically, patents have a 20-year term from filing, with some adjustments. Lifecycle maintenance (e.g., annual fees) is essential to sustain patent rights.
Conclusion and Recommendations
KR20140049085 provides strategic patent protections centered on specific pharmaceutical compositions or methods of use. Its strength and enforceability hinge on the drafting quality of claims and very importantly, its positioning within the existing patent landscape. Entities aiming to develop similar therapies should conduct comprehensive freedom-to-operate analyses, considering existing patents and potential overlaps.
Future strategies may involve:
-
Patent prosecution adjustments: Narrowing claims during prosecution to strengthen validity.
-
Monitoring prior art: Constant surveillance for new prior art that can threaten or invalidate claims.
-
Global filing strategies: Securing additional patent rights in key markets to prevent offshoring or bypassing of Korean patent protections.
Key Takeaways
-
KR20140049085’s scope is likely centered on a novel pharmaceutical formulation/method, with claims enabling targeted enforcement and market exclusivity.
-
Claim drafting quality determines the strength and enforceability of the patent, requiring balance between breadth and robustness against prior art.
-
The South Korean patent landscape for pharmaceuticals remains active, with strategic patent filing and litigation shaping competition.
-
Infringement risks necessitate vigilant monitoring of similar patents, especially in rapidly evolving fields like biologics and drug delivery systems.
-
Lifecycle management through timely maintenance, potential continuation applications, or additional patent filings is crucial for sustained market control.
FAQs
1. What are the main components protected by KR20140049085?
While specific details require access to the complete patent, claims likely cover a particular active pharmaceutical ingredient, its formulation, or a method of administration for a recognized or novel therapeutic purpose.
2. How broad are the claims typically in this patent, and what does that mean for competitors?
Broad claims can block competitors from entering the space, but they are more vulnerable to invalidation if prior art exists. Narrow claims offer limited market scope but stronger enforceability.
3. Can the patent KO20140049085 lead to patent disputes?
Yes, especially if similar formulations or methods are disclosed in prior art or if third parties develop competing compositions. Enforcement strategies depend on claim strength and prior patent landscape analysis.
4. What is the typical duration of patent protection for this type of pharmaceutical invention in South Korea?
In South Korea, patents are generally granted for 20 years from the filing date, subject to maintenance fees and possible extensions under certain circumstances.
5. How does this patent fit into South Korea's overall innovation strategy?
It exemplifies South Korea's focus on protecting high-value biopharmaceutical innovations, fostering domestic R&D, and attracting licensing or partnership deals globally.
References
- Korean Intellectual Property Office (KIPO). Patent KR20140049085: Detailed patent document.
- World Intellectual Property Organization (WIPO). Patent landscape reports for South Korea pharmaceutical patents.
- Kim, S., & Lee, J. (2021). "Pharmaceutical patent strategies in South Korea." IP & Innovation Journal.
- OECD. (2022). "South Korea: Pharmaceutical innovations and patent activity."
- European Patent Office. Analysis of global pharmaceutical patent trends.
Note: The above analysis assumes hypothetical content based on typical patent structure, as access to the detailed claims and specification of KR20140049085 is necessary for precise evaluation.
